普祺医药递表港交所，中信证券和民银资本担任联席保荐人

Core Viewpoint - Puxi Pharmaceutical has submitted its listing application to the Hong Kong Stock Exchange, with CITIC Securities and Minyin Capital acting as joint sponsors [1] Group 1: Company Overview - Puxi Pharmaceutical is a biotechnology company focused on the field of immune inflammation [1] - The company’s product, Pumexitin gel, is a JAK inhibitor gel for the treatment of atopic dermatitis, which has completed Phase III clinical trials for adults and adolescents aged 12 to 17, and is expanding to children aged 2 to 11 [1] - Pumexitin nasal spray is the world's first clinical-stage JAK inhibitor nasal spray for the treatment of seasonal allergic rhinitis, currently in Phase III clinical trials for adults and expanding to adolescents with seasonal allergic rhinitis and adults with perennial allergic rhinitis [1]